Click Therapeutics

Click Therapeutics develops prescription digital therapeutics: clinically proven treatments delivered to patients' smartphones. The company has worked in the Digital Therapeutics category since 2012 and employs around 130 people across four offices in New York, Boston, Miami and Raleigh.

Its lead product, CT-152 (Rejoyn™), is a prescription digital therapeutic for Major Depressive Disorder and the first and only FDA-cleared prescription app for adjunctive MDD treatment; it was developed in collaboration with Otsuka Pharmaceutical. CT-132, a treatment for episodic migraine, met its primary endpoint in the pivotal ReMMi-D trial. A wider pipeline covers psychiatry, neurology, oncology, immunology and cardiometabolic diseases, including Type 2 Diabetes.

Work at the company sits at the intersection of neuroscience and software engineering. Technical domains include artificial intelligence and machine learning, personalised interventions, and the study of cognitive, behavioural and neuromodulatory mechanisms of action, all applied within the framework of FDA-regulated software as a medical device. The culture is interdisciplinary and mission-driven, with a collaborative research and development model conducted alongside pharmaceutical partners such as Otsuka Pharmaceutical and Boehringer Ingelheim.